Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$236.34 USD
-5.84 (-2.41%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $236.50 +0.16 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.34 USD
-5.84 (-2.41%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $236.50 +0.16 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.